Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response, efficacy and safety of Hyper-Ig GC5131 in patients with COVID-19
KCT0005649Phase 2Completed
- Sponsor
- Korea Drug Development Fund
- Start
- Sep 2020
- Modality
- Anti-infectious Disease mAbs → Neutralizing Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gc5131 in coronavirus disease 2019 (COVID-19), sponsored by Korea Drug Development Fund. Started Sep 2020; status: completed.
02
Drugs
gc5131
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on KCT0005649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005649.